In individuals with certain malignant tumours such as PTC, pancreatic neuroendocrine neoplasm, small cell lung cancer and Merkel cell carcinoma, loss of CD56 expression has been linked to malignant transformation, tumour growth and a dismal prognosis [24–27]. Here, NCAM1 is linked to pancreatic neuroendocrine neoplasm.